

Table S3: Predicted number of binding HLA class I alleles for the vaccine-specific core epitopes (9mers listed in Supplementary Table S1) grouped by target TAAs.

Patient	HLA class I Genotype	Number of autologous HLA class I alleles predicted to bind the core (9mer) peptides											
		TSP50		EPCAM		SURVIVIN		CAGE1		FBXO39		MAGE-A8	SPAG 9
		P1A	P1B	P2A	P3A	P2B	P6B	P6A	P7A	P8A	P8B	P3B	P7B
01-0001	A*02:01 B*07:02 C*03:04 A*11:01 B*40:01 C*07:02	3	0	5	1	2	1	1	3	3	1	3	3
01-0002	A*02:01 B*07:02 C*07:02 A*31:01 B*15:01 C*15:02	2	0	4	0	3	0	3	4	3	1	2	2
01-0003	A*03:01 B*07:02 C*07:02 A*26:08 B*08:01 C*07:02	1	1	2	0	2	1	1	1	3	4	1	3
01-0004	A*03:01 B*07:02 C*03:03 A*32:01 B*15:01 C*07:02	1	0	4	0	3	0	3	3	2	2	2	1
01-0005	A*24:02 B*07:02 C*01:02 A*68:01 B*27:05 C*07:02	1	2	3	1	2	1	3	2	2	1	2	2
01-0007	A*01:01 B*08:01 C*06:02 A*25:01 B*37:01 C*07:01	1	4	0	2	0	1	0	0	4	4	0	2
01-0008	A*02:01 B*07:02 C*03:04 A*02:01 B*40:01 C*07:02	3	0	5	1	2	1	2	4	4	1	4	4
02-0001	A*02:01 B*40:02 C*04:01 A*30:02 B*57:02 C*15:02	3	0	3	1	2	1	4	5	2	2	2	1
02-0002	A*02:01 B*50:01 C*06:02 A*03:01 B*50:01 C*06:02	1	2	0	1	0	0	4	1	5	3	1	3
02-0003	A*02:01 B*18:01 C*07:01	2	3	1	1	1	1	1	1	3	5	1	1

Hubbard et al, Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase 1b study

	A*26:01 B*18:03 C*07:01												
02-0004	A*02:01 B*40:02 C*02:02 A*02:12 B*51:01 C*14:02	4	0	3	1	1	1	3	3	4	1	3	3